AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listing of claims in the application.

Listing of Claims

1. **(Currently Amended)** A composition comprising an antibody, or fragment thereof, formulated with DTPA and ~~an agent selected from the group consisting of~~ DEF~~,~~ ~~mannitol, methionine, and histidine, in an amount effective to protect the antibody, or fragment thereof, against oxidation~~.

2. **(Withdrawn - Currently Amended)** The composition of claim 1,further comprising ~~DEF~~ an agent selected from the group consisting of mannitol, methionine, and histidine.

3. **(Original)** The composition of claim 1, further comprising EGTA.

4. **(Original)** The composition of claim 1, wherein the concentration of DTPA is from about 1 μM to about 10 mM.

5. **(Withdrawn- Currently Amended)** The composition of claim 1 ~~2~~, wherein the concentration of DEF is from about 1 μM to about 5 mM.

6. **(Currently Amended)** The composition of claim ~~1~~ 2, comprising mannitol at a concentration of about 0.01% to about 25%.

7. **(Withdrawn-Currently Amended)** The composition of claim ~~1~~ 2, comprising methionine at a concentration of about 10 μM to about 200 mM.

8. **(Withdrawn- Currently Amended)** The composition of claim ~~1~~ 2, comprising histidine at a concentration of about 100 μM to about 200 mM.

9. **(Original)** The composition of claim 1, further comprising an agent that inhibits protein aggregation.

10. **(Original)** The composition of claim 9, wherein the agent that inhibits protein aggregation is selected from the group consisting of polysorbate 80, polysorbate 20, glycerol, and a poloxamer polymer.

11. **(Original)** The composition of claim 10, wherein the agent that inhibits protein aggregation is polysorbate 80 or polysorbate 20 at a concentration of from about 0.001% to about 0.1%.

12. **(Original)** The composition of claim 1, further comprising a buffer that maintains the pH of the composition from about 5.0 to about 8.0.

13. **(Original)** The composition of claim 12, wherein the buffer is selected from the group consisting of phosphate, citrate, Tris, acetate, MES, succinic acid, PIPES, Bis-Tris, MOPS, ACES, BES, TES, HEPES, EPPS, ethylenediamine, phosphoric acid, and maleic acid.

14. **(Currently Amended)** The composition of claim 1, <u>further</u> comprising mannitol, a polysorbate, Tris, and sodium chloride.

15. **(Previously Presented)** The composition of claim 1, wherein the concentration of the antibody is from about 1 μg/mL to about 500 mg/mL.

16. **(Canceled)**

17. **(Previously Presented)** The composition of claim 1, wherein the antibody is a monoclonal antibody, or a fragment thereof.

18. **(Previously Presented)** The composition of claim 1, wherein the antibody is a human antibody, or a fragment thereof.

19. **(Previously Presented)** The composition of claim 1, wherein the antibody or fragment thereof is conjugated to an agent, selected from the group consisting of a toxin, a polymer, an imaging agent and a drug.

20. **(Previously Presented)** The composition of claim 1, wherein the antibody or fragment thereof is microencapsulated.

21. **(Original)** The composition of claim 1, wherein the composition is a pharmaceutical composition.

22. **(Withdrawn)** A composition comprising an antibody or fragment thereof formulated with EGTA and DEF.

23. **(Currently Amended)** A method for preparing a stabilized protein composition, comprising formulating an antibody, or fragment thereof, together with DTPA and ~~an agent selected from the group consisting of~~ DEF~~, mannitol, methionine, and histidine,~~ in an amount effective to protect the antibody, or fragment thereof, against oxidation.

24. **(Withdrawn-Currently Amended)** The method of claim 23, <u>further</u> comprising ~~DEF~~ an agent selected from the group consisting of mannitol, methionine, and histidine.

25. **(Original)** The method of claim 23, wherein the composition further comprises EGTA.

26. **(Currently Amended)** The method of claim <u>25</u> ~~23~~, wherein the concentration of DTPA or EGTA is from about 1 μM to about 10 mM.

27. **(Withdrawn-Currently Amended)** The method of claim <u>23</u> ~~24~~, wherein the concentration of DEF is from about 1 μM to about 5 mM DEF.

28. **(Currently Amended)** The method of claim <u>24</u> ~~23~~, wherein the <u>agent</u> ~~oxidation protective compound~~ is selected from the group consisting of about 0.01% to about 25% mannitol, about 10 μM to about 200 mM histidine, and about 10 μM to about 200 mM methionine.

29. **(Original)** The method of claim 23, further comprising adding an agent that inhibits protein aggregation to the composition.

30. **(Original)** The method of claim 23, further comprising adding a buffer that maintains the pH from about 5.0 to about 8.0 to the composition.

31. **(Original)** The method of claim 30, wherein the buffer is selected from the group consisting of about 5 mM to about 100 mM phosphate, citrate, Tris, acetate, MES,

succinic acid, PIPES, Bis-Tris, MOPS, ACES, BES, TES, HEPES, EPPS, ethylenediamine, phosphoric acid, and maleic acid.

32. **(Currently Amended)** The method of claim 23, wherein the composition <u>further</u> comprises mannitol, a polysorbate, Tris, and sodium chloride.

33. **(Previously Presented)** The method of claim 23, wherein the concentration of the antibody or fragment thereof is from about 1 μg/mL to about 500 mg/mL.

34. **(Canceled)**

35. **(Previously Presented)** The method of claim 23, wherein the antibody is a human antibody, or a fragment thereof.

36. **(Previously Presented)** The method of claim 23, wherein the antibody is a monoclonal antibody, or a fragment thereof.

37. **(Previously Presented)** The method of claim 23, wherein the antibody or fragment thereof is conjugated to an agent selected from a toxin, a polymer, an imaging agent or a drug.

38. **(Previously Presented)** The method of claim 23, wherein the antibody or fragment thereof is microencapsulated.

39. **(Original)** The method of claim 23, wherein the composition is a pharmaceutical composition.

40. **(Canceled)**

41. **(Withdrawn)** A method for preparing a stabilized protein composition, comprising formulating an antibody or fragment thereof together with EGTA and DEF.

42. **(Withdrawn)** The method of claim 41, wherein the antibody or fragment thereof is protected against oxidation.

43. **(New)** The composition of claim 22, further comprising an agent selected from the group consisting of mannitol, methionine, and histidine.

44. **(New)** The method of claim 41, further comprising an agent selected from the group consisting of mannitol, methionine, and histidine.